Table 3 Recurrence events.

From: Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

IDFS events

All patients

(n = 647)

Cohort 1

(n = 351)

Cohort 2

(n = 107)

Cohort 3

(n = 189)

Total IDFS events

111

78

15

18

 Patients with invasive disease, first occurrence

108

76

15

17

  Local/regional recurrence

26

17

4

5

  Distant recurrence

67

57

6

4

  Contralateral recurrence

4

2

0

2

  Second primary neoplasm

20

8

5

7

 Death from any cause without invasive disease

3

2

0

1

DRFS events

 Total DRFS events

79

63

8

8

 Patients with distant relapse, any time

69

59

6

4

  Bone

40

34

2

4

  Liver

19

17

1

1

  Lung

15

12

2

1

  Brain

3

3

0

0

  Lymph node

16

16

0

0

  Pleura

1

1

0

0

  CNS

2

1

1

0

  Othera

2

2

0

0

 Death from any cause without distant recurrence

10

4

2

4

  1. a: included two cases with stomach metastasis.
  2. Abbreviations: IDFS, invasive disease-free survival; DRFS, distant relapse-free survival; CNS, central nervous system.
  3. Cohort 1: Patients with ≥ 4 positive axillary lymph nodes (ALNs), or 1–3 positive ALNs, and either histological grade (HG) 3 or tumor size ≥ 5 cm.
  4. Cohort 2: Patients with 1–3 positive ALNs, HG < 3, tumor size < 5 cm, and high Ki-67 index (≥ 20%).
  5. Cohort 3: Patients with 1–3 positive ALNs, HG < 3, tumor size < 5 cm, and low Ki-67 index (< 20%).
Back to article page